CSI Market
Sign In | Register

Vivos Therapeutics Inc (VVOS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VVOS Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Vivos Therapeutics Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-26.44
Depreciation & amortization1.57
Amortization of Other Assets0.40
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.79
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Common Stock For Settlements-
Warrants Issued For Settlements-
Accretion Of Discount On Convertible Debt-
Accretion Of Discount On Note Receivable-
Noncash Lease Expense-
Increase Decrease In Operating Lease Liability0.02
Derivative Gain Loss On Derivative Net-
Excess Warrant Fair Value-
Increase Decrease In Contract With Customer Liability0.02
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.14
Increase (Decrease) in Accounts Payable1.27
Increase (Decrease) in Accrued Liabilities1.05
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.27
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-0.11
Payments for (Proceeds from) Other Operating Activities12.19
Discontinued operations0.00
Net Cash flow from Operating Activities-9.16
Investing Activities
Capital Expenditures-0.43
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Payments for (Proceeds from) Businesses and Interest in Affiliates0.00
Accounts payable0.00
Proceeds from Sale of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.03
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.43
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings3.03
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.83
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock2.67
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.18
Payments For Deferred Offering Costs-
Proceeds From Exercise Of Prefunded Warrants0.07
Proceeds From Issuance Of Prefunded Warrants-
Finance Lease Principal Payments-0.01
Reduction Of Debt Liability-0.41
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.34
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-9.59
Total Cash Flow-0.26
4 historic quarters locked

Sign in to unlock the full Vivos Therapeutics Inc cash flow history.

Sign In Create Free Account

About Vivos Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-038336

Figures are derived from filed reports and may be restated. Historical data is subject to revision.